ACI-7104.056
Protein Target: alpha-synuclein
AC Immune
Most recent annual filing: 2026-03-13
Pipeline (11 active programs)
ACI-24.060
Protein Target: amyloid beta
semorinemab
ACI-35.030 · JNJ-64042056 · JNJ-2056 Protein Target: phosphorylated Tau, Tau
ACI-19764
Small Molecule Target: NLRP3
- Undisclosed indication
crenezumab
Protein Target: amyloid beta
PI-2620
LNTH-2620 Small Molecule Target: Tau
ACI-12589
Small Molecule Target: alpha-synuclein
ACI-15916
Small Molecule Target: alpha-synuclein
ACI-19626
Small Molecule Target: TDP-43
Technology platforms
SupraAntigen
Liposome-based antigen presentation platform generating conformation-specific antibodies for active immunotherapy targeting misfolded proteins in neurodegenerative diseases; focus areas include Alzheimer's disease and Parkinson's disease
Targets: amyloid beta, phosphorylated Tau, alpha-synuclein
Morphomer
Small molecule discovery platform selecting brain-penetrant compounds targeting misfolded protein aggregates intracellularly; generates both therapeutic and diagnostic (PET tracer) candidates for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, FTD, and ALS
Targets: Tau, alpha-synuclein, TDP-43, NLRP3
Biotech Distilled coverage (1)
- 2026-06-01 AC Immune SA (ACIU) — Scientific Deep Dive for ACI-7104.056 and the SupraAntigen/Morphomer Pipeline 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.